Atyr Pharma, Inc. · NASDAQ:ATYR
Atyr Pharma — Investor Presentation (January 2018)
18 slides from Atyr Pharma's investor presentation, Jan 8, 2018
Slide 1: Corporate Presentation January 2018
Harnessing Newly Discovered Pathways in Immunology Effected by Extracellular tRNA Synthetases CORPORATE PRESENTATION January 2018 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,”
Slide 3: Accelerating Value Creation from Novel Immune Pathways
Accelerating Value Creation from Novel Immune Pathways Research: Discover innovative therapeutic candidates based on extracellular functionality of tRNA synthetases Initial focus on extracellular histidyl-tRNA synthetase (HARS) Development: ATYR1923 (interstitial lung diseases) in ongoing Phase 1 tr
Slide 4: Therapeutic Candidate Pipeline
Therapeutic Candidate Pipeline Resokine Pathway DISCOVERY Preclinical Phase 1 Phase 2 Phase 3 ATYR1923 (Engineered HARS)* Interstitial Lung Disease ORCA (HARS antibodies) Various Cancers ATYR1940 (~Full-length HARS) Rare Muscular Dystrophies tRNA Synthetase Pipeline DISCOVERY Preclinical Phase 1 Pha
Slide 5: Resokine: Extracellular Proteins Derived From HARS Gene
AARS CARS DARS EPRS FARS GARS HARS IARS KARS LARS MARS NARS QARS RARS SARS TARS VARS WARS YARS Full-length HARS Splice variant of HARS One example of multiple splice variant proteins Extracellular: (Circulation) Intracellular: (Cytoplasm) Secretion Resokine: Extracellular Proteins Derived From HARS
Slide 6: Resokine MOA Hypothesis: Regulates T Cell Activation
Stimulatory pathways at levels closer to a resting T cell Effector functions at levels closer to a resting T cell Resokine MOA Hypothesis: Regulates T Cell Activation Acts on both CD4 and CD8 T cells Shifts trafficking and residence closer to a resting T cell
Slide 7: Resokine Regulates T Cell Activation
Resokine Regulates T Cell Activation Similar for: INFγ, TNFα… Similar to hitting PD-1 pathway Anti-CD3/CD28 (24 hr.) Stimulation + Vehicle T cell Activation Marker CD4+ T cell count Anti-CD3/CD28 Stimulation + Resokine (100pM) T cell Activation Marker CD4+ T cell count Graphs on Right: T cells were
Slide 8: Engineered HARS Splice Variant (iMod.Fc) ATYR1923 for Interstitial Lung Diseases
Engineered HARS Splice Variant (iMod.Fc) ATYR1923 for the Treatment of Interstitial Lung Diseases
Slide 9: ATYR1923: Program Snapshot
ATYR1923: Program Snapshot ATYR1923 (iMod.Fc): Engineered fusion protein with HARS splice variant Refer to splice variant as the “iMod domain” (iMod for immuno-modulatory function) Patients: Interstitial lung diseases (ILDs) characterized by an immune component Mechanism: Regulation of T cell activa
Slide 10: Interstitial Lung Diseases Share Persistent Immune Engagement
Slide adapted from Dr. Steven Nathan, Medical Director, Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Falls Church, VA Interstitial Lung Diseases Share Persistent Immune Engagement Fibrotic Sarcoidosis Systemic Sclerosis – ILD (SSc-ILD) Chronic Hypersensitivity Pneumonitis
Slide 11: ATYR1923 Ameliorates Fibrosis in Bleomycin-Induced Lung Injury
ATYR1923 Ameliorates Fibrosis in Bleomycin-Induced Lung Injury Experiment 1 Experiment 2 ATYR1923 (iMod.Fc) administered therapeutically at 0.4 mg/kg weekly drives efficacy comparable to or greater than Pirfenidone*, anti-TGF antibodies, and dexamethasone *Pirfenidone: Current approved therapy for I
Slide 12: ATYR1923 Clinical Development for Interstitial Lung Diseases
ATYR1923 Clinical Development for Interstitial Lung Diseases Clinical Overview Randomized, double-blind, placebo-controlled studies to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous ATYR1923 (iMod.Fc) in healthy volunteers and patients with
Slide 13: Antibodies to the Resokine Pathway: ORCA
Antibodies to the Resokine Pathway ORCA – Targeting a Novel Immune Set Point for Cancer Patients
Slide 14: Regulating T Cells to Temper or Enhance Anti-Tumor Immunity
Regulating T Cells to Temper or Enhance Anti-Tumor Immunity Resokine “Agonist” Regulates T cell activation with potential to temper immune system ORCA “Antagonist” Unlocks T cell activity with potential to enhance anti-tumor immunity
Slide 15: Anti-Synthetase Syndrome: Evidence of Resokine Pathway Relevance
Anti-Synthetase Syndrome: Evidence of Resokine Pathway Relevance in a Human Disease Setting Healthy Tissue T Cells Mobilized in Tissue Resokine acts as homeostatic regulator of immune activity Antibodies to Resokine lower threshold for T cell activation Resokine disruption via auto-antibodies Health
Slide 16: ORCA Program: Snapshot
ORCA Program: Snapshot Patients: Potentially all cancer types: >450 patient samples in over 10 tumor types tested ~95% of cancer patients tested positive for Resokine Target: Resokine pathway Therapeutic Concept: Antibody to block Resokine activity, increases T cell engagement Rationale: Human evide
Slide 17: ORCA Program: Supportive In Vivo Data and Development Timelines
ORCA Program: Supportive In Vivo Data and Development Timelines Development Timelines In Vivo Efficacy Data Resokine antibody selection: Panel of antibodies selected and in IND enabling activities Present Data at Scientific Conferences: Abstract at ASCO-SITC in January 2018 Additional presentations
Slide 18: Accelerating Value Creation from Novel Immune Pathways: 2018 Strategic Goals
Accelerating Value Creation from Novel Immune Pathways 2018 Strategic Goals: Advance Clinical Development ATYR1923 Phase 1 ongoing with data in 2Q 2018 Advance Immuno-Oncology Program IND-enabling activities ongoing for patient trials in 2019 Discovery and Pipeline Enhancement Collaborating with aca